<!DOCTYPE html>
<html lang="en">

<head>

  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta name="title" content="Content | CAPA Consulting ‚Äì Content published by CAPA Consulting">

  <meta name="description" content="Explore QA case studies, GMP updates, regulatory changes, and expert insights from CAPA Consulting. Navigate Compliance Management, Annex 22, and proactive quality strategies with real-world examples." />
  <meta name="keywords" content="GMP updates, GDP changes, QA insights, CAPA Consulting, Annex 22, Compliance Management, EU regulations, pharma quality, QMS optimization, risk-based QA, proactive compliance" />
  <meta name="author" content="CAPA Consulting" />
  <link rel="canonical" href="https://www.capaconsulting.be/content" />

  <meta property="og:type" content="website" />
  <meta property="og:title" content="CAPA Consulting ‚Äì Quality Insights, Updates & Case Learnings" />
  <meta property="og:description" content="Discover in-depth quality assurance knowledge, including AI regulation in GMP, GDP transformation, and how to avoid costly compliance failures." />
  <meta property="og:url" content="https://www.capaconsulting.be/content" />
  <meta property="og:image" content="https://www.capaconsulting.be/logo-center-home.png" />


  <link rel="icon" href="/favicon.ico" type="image/x-icon">
  <link rel="icon" href="logo-small-home.png">
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter+Tight:ital,wght@0,100..900;1,100..900&display=swap" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css2?family=Frank+Ruhl+Libre:wght@300..900&display=swap" rel="stylesheet">

  <script src="https://cdn.jsdelivr.net/npm/gsap@3.12.7/dist/gsap.min.js"></script>
  <script src="https://cdn.jsdelivr.net/npm/gsap@3.12.7/dist/ScrollToPlugin.min.js"></script>
  <script src="https://cdn.jsdelivr.net/npm/gsap@3.12.7/dist/ScrollTrigger.min.js"></script>
  <script>
      (function(h,o,t,j,a,r){
      h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
      h._hjSettings={hjid:5326149,hjsv:6};
      a=o.getElementsByTagName('head')[0];
      r=o.createElement('script');r.async=1;
      r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
      a.appendChild(r);
      })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
  </script>

  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "Organization",
    "name": "CAPA Consulting",
    "url": "https://www.capaconsulting.be",
    "logo": "https://www.capaconsulting.be/logo-center-home.png",
    "email": "nicolas@CAPAconsulting.be",
    "description": "CAPA Consulting provides expert QA, QP/RP, and compliance services for the pharmaceutical and medical device industries in Belgium and Europe.",
    "address": {
      "@type": "PostalAddress",
      "addressCountry": "BE"
    },
    "contactPoint": {
      "@type": "ContactPoint",
      "email": "nicolas@CAPAconsulting.be",
      "contactType": "customer support",
      "areaServed": "BE",
      "availableLanguage": ["English", "French", "Dutch"]
    }
  }
  </script>

	<title>CAPA Consulting ‚Äì Content</title>

<style>
  body { 
    margin: 0px;
  }

  body::-webkit-scrollbar {
    width: 0.25rem;
  }
  
  body::-webkit-scrollbar-track {
    background: rgba(250,250,252,0.8);
  }
  
  body::-webkit-scrollbar-thumb {
    background: #1d1d1f;
  }

* {
  -webkit-tap-highlight-color: rgba(29, 29, 31, 0.5);
}
  .header-container-outer {  
    display: grid;
    grid-template-columns: 1fr minmax(0,1100px) 1fr;
    grid-template-rows: 45px 0px;
    background-color: rgba(250,250,252,0.8);
    position: sticky;
    top: 0;
    transition: 200ms ease;
    z-index: 1;
  }

  .header-container-outer:hover {  
    grid-template-rows: 45px 100px;
    transition: 200ms ease;
  }

  .header-container-inner {
    display: grid;
    width: 100%;
    grid-template-columns: 0.2fr 1fr 1fr 1fr 1fr 1fr;
    grid-column-start: 2;
    grid-column-end: 3;
    font-family: "Inter Tight", sans-serif;
    font-size: 12px;
    font-weight: 400;
    justify-content: stretch;
    align-items: center;
    color: #1d1d1f;
    overflow: visible;
  }

  .header-element-image {
    width: 12px;
    padding: 10px;
  }

  .header-element-text {
    justify-self: end;
    color: inherit;
    text-decoration: none;
    padding-right: 5px;
  }

  .header-element-services-container {
    grid-row: 2;
    grid-column: 2;
    opacity: 0;
    display: grid;
    grid-template-columns: 1fr;
    margin-top: 10px;
    gap: 15px;
    transition: opacity 200ms ease;
    justify-items: end;
    align-items: end;
  }

  .header-container-outer:hover .header-element-services-container {
    opacity: 1;
  }

  .header-element-text-services {
    display: block;
    color: inherit;
    text-decoration: none;
  }

  .footer-container-outer {  
    display: grid;
    grid-template-columns: 1fr minmax(0,1100px) 1fr;
    grid-template-rows: 90vh;
    background-color: white;
    grid-gap: 12px;
    overflow-x: hidden;
  }

  .footer-container-inner {
    display: grid;
    grid-template-rows: 0.1fr 0.33fr 0.66fr;
    grid-template-columns: 1fr minmax(0,1100px) 1fr;
    grid-column: 1/4;
    background-color: #333336;
  }

  .sub-container-footer-top {
    display: grid;
    grid-column: 2/3;
    grid-row: 2/3;
    grid-template-columns: 2fr repeat(3, 1fr) 2fr;
  }

  .sub-container-footer-bottom {
    display: grid;
    grid-column: 2/3;
    grid-row: 3/4;
  }

  .sub-sub-container-footer-top {
    display: grid;
    grid-template-rows: 1fr 1fr 1fr;
  }

  .footer-logo {
    justify-self: center;
    align-self: center;
    height: 250px;
  }

  .footer-text-middle {
    justify-self: center;
    align-self: start;
    font-family: "Inter Tight", sans-serif;
    font-size: 17px;
    font-weight: 400;
    color: #e8e8ed;
    padding: 0;
    margin: 0;
  }

  .footer-text-right {
    justify-self: end;
    align-self: start;
    font-family: "Inter Tight", sans-serif;
    font-size: 17px;
    font-weight: 400;
    color: #e8e8ed;
    padding: 0;
    margin: 0;
  }

  .footer-text-left-row-1 {
    grid-row: 1;
    justify-self: start;
    align-self: start;
    font-family: "Inter Tight", sans-serif;
    font-size: 17px;
    font-weight: 400;
    color: #e8e8ed;
  }

  .footer-text-left-row-2 {
    grid-row: 2;
    justify-self: start;
    align-self: start;
    font-family: "Inter Tight", sans-serif;
    font-size: 17px;
    font-weight: 400;
    color: #e8e8ed;
    padding: 0;
    margin: 0;
  }

  .bold {
    font-weight: 700;
    padding: 0;
    margin: 0;
  }

  .antibototics {
    padding-top: 5px;
    height: 19px;
  }




  .main-container-outer {  
    display: grid;
    grid-template-columns: 1fr minmax(0,550px) 1fr;
    grid-template-rows: auto auto auto;
    background-color: #f5f5f7;
    overflow-x: hidden;
  }

  .main-container-inner-1 {
    display: grid;
    background-color: #f5f5f7;
    grid-template-columns: 38% 62%;
    grid-column: 2/3;
    grid-row: 1/2;
  }

  .symbol-top {
    grid-row: 1/2;
    grid-column: 1/2;
    max-height: 100%;
    height: 100px;
    justify-self: center;
    padding-top: 10px;
  }

  .text-top-title-div {
    grid-row: 1/2;
    grid-column: 2/3;
    align-self: end;
    justify-self: center;
  }

  .main-container-inner-2 {
    display: grid;
    background-color: #f5f5f7;
    grid-column: 2/3;
    grid-row: 2/3;
  }

  .menu-background {
    background-color: #ffffff;
    border-radius: 12px;
    padding: 10px;
    margin: 5px;
    justify-self: stretch;
  }



  .text-top-title-p {
    font-family: "Frank Ruhl Libre", serif;
    font-size: 4em;
    font-optical-sizing: auto;
    font-weight: 300;
    font-style: normal;
    align-self: center;
    color: #1d1d1f;
    margin-bottom: 40px;
  }

  .text-subtitle-p {
    font-family: "Inter Tight", sans-serif;
    font-size: 20px;
    font-weight: 500;
    color: #1d1d1f;
    padding: 0;
    margin: 0;
    text-align: justify;
  }

  .text-body-p {
    font-family: "Inter Tight", sans-serif;
    font-size: 17px;
    font-weight: 400;
    color: #1d1d1f;
    padding: 0;
    margin: 0;
    text-align: justify;
  }


  .case-grid {
    display: grid;
    grid-template-columns: 1fr; 
    margin: 10px;
    padding: 20px;
    margin-bottom: 40px;
    width: 1fr;
  }

  .case {
    border: 1px solid #ccc;
    border-top-left-radius: 8px;
    border-top-right-radius: 8px;
    margin-top: 20px;
    overflow: hidden;

  }


  .case-title {
    padding: 15px 20px;
    background: #f5f5f7;
    cursor: pointer;
  }

  .case-content {
    max-height: 0;
    overflow: hidden;
    transition: max-height 0.4s ease, padding 0.3s ease;
    padding: 0 20px;
  }

  .case-media {
    width: 100%;
    overflow: hidden;
    cursor: pointer;
    border-bottom-left-radius: 8px;
    border-bottom-right-radius: 8px;
  }

  .case.open .case-content {
   }

  .content-container {
    display: grid;
    grid-template-rows: auto auto auto;
  }



    .carousel {
      width: 100%;
      max-width: 800px;
      overflow: hidden;
      margin: 0 auto;
      position: relative;
      border-left: 1px solid #ccc;
      border-right: 1px solid #ccc;
      border-bottom: 1px solid #ccc;
      border-bottom-left-radius: 8px;
      border-bottom-right-radius: 8px;
  box-sizing: border-box;

    }

    .carousel-track {
      display: flex;
      will-change: transform;
    }

    .carousel-slide {
      flex-shrink: 0;
    }

    .carousel-slide img {
      width: 100%;
      height: auto;
      display: block;

    }

    .controls {
      text-align: center;
      margin-top: 10px;
    }

.carousel-controls {
  position: absolute;
  bottom: 10px;
  left: 50%;
  transform: translateX(-50%);
  display: flex;
  gap: 10px;
  z-index: 10;
}

.carousel-controls button {
  width: 40px;
  height: 40px;
  border-radius: 50%;
  border: none;
  background-color: rgba(0, 0, 0, 0.4);
  color: white;
  font-size: 18px;
  cursor: pointer;
  display: flex;
  align-items: center;
  justify-content: center;
  transition: background-color 0.2s ease;
}

.carousel-controls button:hover {
  background-color: rgba(0, 0, 0, 0.6);
}

.visually-hidden {
  position: absolute;
  width: 1px;
  height: 1px;
  padding: 0;
  margin: -1px;
  overflow: hidden;
  clip: rect(0, 0, 0, 0);
  white-space: nowrap;
  border: 0;
}

  .main-container-inner-3 {
    display: grid;
    grid-template-columns: 1fr minmax(0,1100px) 1fr;
    background-color: #ffffff;
    grid-column: 1/4;
    grid-row: 3/4;
  }



  .sub-container-inner-4 {
    display: grid;
    grid-template-rows: auto auto auto;
    grid-column: 2/3;
    grid-row: 4/5;
  }

  .button-layout-div {
    grid-row: 3/4;
    place-self: center;
    margin: 50px;
  }

  .button-layout {
    background-color: transparent;
    border: 1px solid #1d1d1f;
    font-family: "Inter Tight", sans-serif;
    font-size: 17px;
    color: #6e6e73;
    padding: 10px;
    margin: 20px;
    border-radius: 20px;
    border-color: #6e6e73;
    text-decoration: none;
  }

  .button-layout:hover {
    background-color: #f5f5f7;
    cursor: pointer;
  }

  .selector2 {}
  .selector3 {
    padding: 10px;
  }


  @media (max-width: 768px) {
    .main-container-outer {  
      grid-template-rows: auto;
    }
    .text-top-title-p {
      padding-left: 10px;
    }
    
    .header-container-inner {
      grid-template-columns: repeat(6, auto);
    }

    .sub-container-footer-top {
      grid-template-columns: 1fr;
      text-align: center;
      justify-items: center;
    }

    .sub-sub-container-footer-top {
      grid-template-rows: auto;
    }

    .text-top-title-div {
    grid-row: 2/3;
    grid-column: 1/2;
    align-self: end;
    justify-self: center;
    }

    .footer-text-middle,
    .footer-text-right,
    .footer-text-left-row-1,
    .footer-text-left-row-2 {
      justify-self: center;
      text-align: center;
    }
    .main-container-inner-1 {
      grid-template-columns: auto;
      grid-template-rows: auto auto;

    }
    .symbol-top {
      padding-top: 40px;
    }

    .footer-logo {
      height: 150px;
    }

    .footer-container-inner {
      grid-template-rows: auto auto auto;
    }

  .case-grid {
    padding: 5px;
  }



  }
</style>

</head>

<body>
	<header class="header-container-outer" role="banner">
		<nav class="header-container-inner" role="navigation">
			<a href="/index" >
				<img src="logo-small-home.png" class="header-element-image">
			</a>


			<p class="header-element-text"> Services </p>
			<a href="/about-CAPA" class="header-element-text">
				About CAPA
			</a>
			<a href="/cases" class="header-element-text">
				Cases
			</a>
      <a href="/content" class="header-element-text">
        Content
      </a>
			<a href="/contact" class="header-element-text">
				Contact Us
			</a>
			<div class="header-element-services-container">
			<a href="/QA-services" class="header-element-text-services">
				QA Services
			</a>
			<a href="/QPRP-services" class="header-element-text-services">
				QP/RP Services
			</a>
			<a href="/QA-optimization" class="header-element-text-services">
				QA Optimization
			</a>
		</div>
		</nav>
	</header>


<main class="main-container-outer">

	<div class="main-container-inner-1">
			<img src="symbol-content.png" alt="Symbol content" class="symbol-top">
			<div class="text-top-title-div">
				<h1 class="text-top-title-p">Content</h1>
			</div>
	</div>

	<div class="main-container-inner-2">

      <div class="case-grid menu-background">





        <div class="case"  style="margin-top: 0px">

          <div class="case-title text-subtitle-p"><strong>The new draft of EU GMP Chapter 1 is here, and it reinforces a crucial trend:</strong>
          </div>

          <div class="case-content">
            <div class="content-container text-body-p">

              <p><strong>Quality Risk Management (QRM)</strong> is no longer just a tool, but a cornerstone of the entire <strong>Pharmaceutical Quality System (PQS)</strong>.<br>
                I've highlighted the changes for you in this carousel. Give it a swipe! ‚û°Ô∏è</p>

                <p>I wholeheartedly applaud the growing emphasis on QRM throughout the chapter. 
                It now more explicitly calls for a <strong>proactive, risk-based approach to quality.</strong></p>

                <p>This is the very essence of what we do at <strong>CAPA Consulting</strong> with our <strong>QA Optimization</strong> services. 
                We leverage QRM as a powerful, systematic process to make informed, risk-based decisions that protect patients and improve processes and business. 
                Seeing this philosophy being embedded deeper into EU GMP is fantastic.</p>

                <p>The future of quality is clear: it will be increasingly risk-based. 
                QRM is the key to building more resilient, efficient, and reliable systems, and its importance will only continue to grow. 
                Rightfully so.</p>

                <p><strong>What are your thoughts on the evolution of QRM in the industry?</strong></p>

                <p>üìå <em>Note: Chapter 1 is currently in draft (stakeholders consultation) until 3rd of December. 
                Nonetheless, it is highly unlikely that the content will undergo major changes from here.</em></p>

            </div>
          </div>

        </div>


       <div class="carousel">
        <div class="carousel-track">
          <div class="carousel-slide"><img src="Dia1c.jpg" alt="Slide 1"></div>
          <div class="visually-hidden">
            <h3>EU GMP Chapter 1 PQS updated draft: In a nutshell</h3>
            <p>
              An overview of the new Chapter 1 draft on Pharmaceutical Quality System (PQS). Date: 08/09/2025. *Modifications in red.
              Date of creation: 08/09/2025
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia2c.jpg" alt="Slide 2"></div>
          <div class="visually-hidden">
            <h3>1. Principle</h3>
            <p>
                The Marketing Authorisation Holder (MAH) must manufacture medicinal products, ensuring that they are: Fit for their intended use; Comply with the requirements of the Marketing Authorisation (or Clinical Trial Authorisation); Do not place patients at risk due to inadequate safety, quality or efficacy. Attaining this so-called ‚Äúquality objective‚Äù is the responsibility of senior management and requires commitment by staff at all levels. The documented and continuously monitored Pharmaceutical Quality System (PQS) is there to achieve this objective reliably. A proactive approach to QRM is of strategic importance in: achieving an effective PQS; achieving continuous improvement; enabling informed and timely decisions throughout the product lifecycle. The basic concepts of Quality Management, GMP and QRM are inter-related. The use of risk-based drug shortage prevention and mitigation activities with respect to product quality/manufacturing risks should be considered.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia3c.jpg" alt="Slide 3"></div>
          <div class="visually-hidden">
            <h3>2. PQS</h3>
            <p>
                Quality Management is the sum total of the organised arrangements made with the objective of ensuring that medicinal products are of the quality required for their intended use. It covers all matters which collectively influence the quality of a product. GMP applies throughout the product lifecycle (from manufacturing of IMPs to tech transfer, to commercial manufacturing and to product discontinuation). A PQS should be commensurate the size and complexity of the activities. The design should incorporate Risk Management principles. Consistent delivery of products with appropriate Quality Attributes by designing, planning, implementing, maintaining and continuously improving the PQS.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia4c.jpg" alt="Slide 4"></div>
          <div class="visually-hidden">
            <h3>What should a PQS ensure? (1/2)</h3>
            <p>
                A PQS should ensure: Management of product and process knowledge throughout the lifecycle. Development of medicinal products in line with GMP requirements. Manufacturing and QC activities in line with GMP requirements. Managerial responsibilities are documented. The manufacture, supply and use of the correct starting and packaging materials. The appropriate selection and monitoring of suppliers. Any outsourced activities are appropriately managed. A state of control is established and maintained by developing and maintaining monitoring and control systems; QRM should be used in the design and validation/qualification of such systems. The results of product and process monitoring are taken into account in batch release, in the investigation of deviations, and, with a view to taking preventive action to avoid potential deviations occurring in the future. All IPCs, relevant checks/analyses during manufacturing and any relevant validations are carried out. Continuous improvement.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia5c.jpg" alt="Slide 5"></div>
          <div class="visually-hidden">
            <h3>What should a PQS ensure? (2/2)</h3>
            <p>
                A PQS should ensure: An appropriate level of root cause analysis is applied during the investigation of deviations, product defects and other problems. Appropriate corrective actions and/or preventive actions (CAPAs) should be identified and taken in response to investigations. The effectiveness of such actions should be monitored and assessed, in line with Quality Risk Management principles. Medicinal products are not sold or supplied before a Qualified Person has certified each production batch. Medicinal products are stored, distributed and subsequently handled so that quality is maintained throughout their shelf life. There is a process for self-inspection and quality audits. QRM, together with knowledge management, is used to provide an early warning system that supports oversight and response to evolving quality/manufacturing risks from the company or its external partners, including potential product shortage issues. Prospective evaluation of planned changes and their approval prior to implementation. After implementation of any change, an evaluation is undertaken to confirm the quality objectives were achieved and that there was no unintended deleterious impact on product quality.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia6c.jpg" alt="Slide 6"></div>
          <div class="visually-hidden">
            <h3>Senior Management</h3>
            <p>
                Senior management has the ultimate responsibility to ensure an effective PQS is in place, adequately resourced and that roles are defined. Senior management‚Äôs leadership and active participation in the PQS is essential. This leadership should ensure the support of staff at all levels within the organisation to the PQS. There should be periodic management review (with the involvement of senior management) of the operation of the PQS to identify opportunities for continuous improvement of products, processes and the system itself.
            </p>
          </div>

          <div class="carousel-slide"><img src="Dia7c.jpg" alt="Slide 7"></div>
          <div class="visually-hidden">
            <h3>3. GMP (1/2)</h3>
            <p>
                Good Manufacturing Practice is that part of Quality Management which ensures that products are consistently produced and controlled to the quality standards. Basic requirements are: All manufacturing processes are defined, systematically reviewed, and shown to be capable of consistently manufacturing products of the required quality. Manufacturing processes and significant changes are validated. All necessary facilities are provided (qualified personnel, adequate premises/equipment/services/materials, approved procedures, suitable storage/transport). Instructions and procedures are clear and unambiguous. External product availability risks are adequately managed. Procedures are carried out correctly by trained operators. Records are made during manufacturing and distribution to demonstrate all steps were taken and product quantity/quality is as expected; records are retained in a clear, accessible form. Any significant deviations are fully recorded, investigated for root cause, and appropriate CAPA is implemented.
            </p>
          </div>

          <div class="carousel-slide"><img src="Dia8c.jpg" alt="Slide 8"></div>
          <div class="visually-hidden">
            <h3>3. GMP (2/2)</h3>
            <p>
                The basic GMP requirements are: The distribution of the products minimises any risk to their quality and takes account of Good Distribution Practice. A system is available to recall any batch of product, from sale or supply. Complaints about products are examined, the causes of quality defects investigated and appropriate measures taken in respect of the defective products and to prevent reoccurrence.
            </p>
          </div>

          <div class="carousel-slide"><img src="Dia9c.jpg" alt="Slide 9"></div>
          <div class="visually-hidden">
            <h3>4. QC</h3>
            <p>
                Quality Control is the part of GMP concerned with sampling and testing, so that materials are not released for use, nor products released for sale, until their quality has been judged satisfactory. Basic QC requirements include: Adequate facilities, trained personnel, and approved procedures for sampling and testing materials and monitoring environmental conditions. Test methods are validated. Records demonstrate all required procedures were carried out and materials are assessed against specification. Finished products contain active ingredients compliant with the Marketing Authorisation, are of the required purity, and are correctly contained and labelled. No batch is released prior to certification by a Qualified Person. Sufficient reference samples of starting materials and products are retained.
            </p>
          </div>

          <div class="carousel-slide"><img src="Dia10c.jpg" alt="Slide 10"></div>
          <div class="visually-hidden">
            <h3>5. PQR</h3>
            <p>
                Periodic Quality Reviews of all authorised medicinal products are conducted to verify the consistency of the process and appropriateness of specifications, to highlight trends, and to identify product and process improvements. Such reviews should take into account previous reviews and include at least: A review of starting and packaging materials (especially supply chain traceability of active substances). A review of in-process controls and finished product results. A review of all batches that failed to meet specification and their investigation. A review of all significant deviations and the effectiveness of resultant CAPAs. A review of all changes made to the processes or analytical methods. A review of Marketing Authorisation variations submitted, granted, or refused. A review of the stability monitoring programme and any adverse trends. A review of all quality-related returns, complaints and recalls. A review of adequacy of any other corrective actions. A review of post-marketing commitments for new authorisations and variations. The qualification status of relevant equipment and utilities. A review of any contractual arrangements.
            </p>
          </div>

          <div class="carousel-slide"><img src="Dia11c.jpg" alt="Slide 11"></div>
          <div class="visually-hidden">
            <h3>5. PQR - Data Usage</h3>
            <p>
                Trending data from the previous product quality review should be included where few batches were manufactured in a 12-month period to ensure a more extensive data set. It can also be useful when a larger number of batches is manufactured. If no batches were manufactured during the review period, the PQR should still be performed. This review should address: stability results, returns, complaints, recalls, relevant deviations, and regulatory background (variations, commitments). A review of the last PQR should also be conducted. Use available data meaningfully. No recent activity still requires a PQR.
            </p>
          </div>

          <div class="carousel-slide"><img src="Dia12c.jpg" alt="Slide 12"></div>
          <div class="visually-hidden">
            <h3>5. PQR - Timeframes & Grouping</h3>
            <p>
                Review timeframes can be adjusted based upon manufacturing and campaign duration, with adequate justification, and criteria should be established in a procedure. The Marketing Authorisation Holder should evaluate the results of the review and assess whether CAPAs or any revalidation should be undertaken, with procedures for ongoing management. Quality reviews may be grouped if scientifically justified and it enhances the overall review, but the strategy should not impede detection of adverse trends for an individual product. Reviewing only a representative or worst-case product is not acceptable.
            </p>
          </div>

          <div class="carousel-slide"><img src="Dia13c.jpg" alt="Slide 13"></div>
          <div class="visually-hidden">
            <h3>6. QRM</h3>
            <p>
                Quality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the medicinal product. Product quality should be assured based on appropriate risk-based decision making throughout the product lifecycle. Knowledge should be used to make informed decisions, trigger re-evaluations and stimulate continuous improvement. The evaluation of risk to quality is based on scientific knowledge, experience, and ultimately links to patient protection. Risk to quality includes situations where product availability may be impacted. Each site in the supply chain should manage any manufacturing/quality risks that could impact product availability. The level of effort, formality and documentation of the QRM process should be commensurate with the level of risk.
            </p>
          </div>

          <div class="carousel-slide"><img src="Dia14c.jpg" alt="Slide 14"></div>
          <div class="visually-hidden">
            <h3>6. QRM - Process</h3>
            <p>
                The output/results of the quality risk management process should be reviewed to take into account new knowledge and experience, with a mechanism to review and monitor events. Subjectivity can directly impact the effectiveness of QRM activities and should be managed and minimised. An appropriate level of formality should be applied, allowing less formal means for lower risk issues, freeing up resources for higher risk issues that require more rigor and effort.
            </p>
          </div>

          <div class="carousel-slide"><img src="Dia15c.jpg" alt="Slide 15"></div>
          <div class="visually-hidden">
            <h3>Need Support?</h3>
            <p>
                Contact Nicolas Van Leeckwyck (apr.), Qualified Person, Founder of CAPA consulting. Offering QP/RP/QA services and QA optimization. Phone: +32 477 31 49 80, Email: nicolas@capaconsulting.be, Website: https://capaconsulting.be. Quality is an investment, not a cost.
            </p>
          </div>
        </div>
        <div class="carousel-controls">
          <button class="prevBtn">&#8592;</button> 
          <button class="nextBtn">&#8594;</button> 
        </div>
      </div>




        <div class="case">
          <div class="case-title text-subtitle-p" > üìö <strong>Why Training Makes All the Difference</strong>
          </div>
          <div class="case-content">
            <div class="content-container text-body-p">
              
              <p>September is here.<br>
              As a QA‚Äôer and a parent, I proudly say: <em>‚ÄúMy daughter returns to school to continue her Training Plan.‚Äù</em></p>

              <p>In Quality Management, it is no different.<br>
              Every standard and regulation requires training. GMP, GDP, ISO13485, the MDR‚Ä¶<br>
              If you boil it down, they all state the same requirement:<br>
              <strong>Initial Training + Continuous Training</strong></p>

              <p><strong>Why?</strong><br>
              Training is what transforms any SOP into Operation. The best-written SOP is useless if it‚Äôs not applied.</p>

              <p>‚úÖ <strong>A strong training system includes:</strong></p>
              <ul>
                <li><strong>Training Matrix</strong> ‚Äì mapping ‚Äúideal profile‚Äù vs. ‚Äúcurrent profile.‚Äù</li>
                <li><strong>Training Plan</strong> ‚Äì personal plan for every employee (especially useful during onboarding).</li>
                <li><strong>Training Logs</strong> ‚Äì chronological logs per individual (your inspector‚Äôs first stop, so keep them clean!).</li>
                <li><strong>Training Records</strong> ‚Äì details for each training: date, duration (track as a KPI), subject, materials, trainer and attendees.</li>
              </ul>

              <p>Oh and‚Ä¶ please do not forget the <strong>Verification of Effectiveness</strong>. 
              Organizing a training without verifying its effectiveness is like running a fire drill without checking if anyone evacuated. 
              It just doesn‚Äôt make sense.</p>

              <p>üëâ <strong>The Reality:</strong><br>
              Training takes a lot of <strong>time and energy</strong>.</p>

              <p>That‚Äôs why <strong>CAPA Consulting</strong> helps QA teams by taking training management off their shoulders.</p>

              <p><strong>Outsourcing means:</strong></p>
              <ul>
                <li>‚úîÔ∏è Trainings designed to deliver the right message in the right way to each target audience.</li>
                <li>‚úîÔ∏è A training system that is always inspection-ready.</li>
                <li>‚úîÔ∏è More time and focus for you to tend to other parts of your QMS.</li>
              </ul>

              <p>üëâ Curious: how do you make sure training <em>actually sticks</em> in your organization?</p>

            </div>
          </div>
        </div>
        <img class="case-media" src="training_image.jpg" alt="Image of a book being transformed to operation by training">






        <div class="case">
          <div class="case-title text-subtitle-p" > üõ°Ô∏è <strong>GDPR in Quality Assurance: 2 Definitions and 4 Rules</strong>
          </div>
          <div class="case-content">
            <div class="content-container text-body-p">
              
              <p>In Quality roles, you frequently handle personal data (complaints, employee info, vigilance data,‚Ä¶). 
              I always knew GDPR applied but never fully understood its scope or practical implications. 
              After taking the time to dive into the regulation, I‚Äôve identified 2 key definitions and 4 general rules that provide a solid foundation for understanding GDPR from a QA perspective.</p>

              <p>üìò <strong>2 Definitions You Should Know:</strong></p>
              <ul>
                <li><strong>Personal data</strong> = any information relating to an identified or identifiable natural person (name, location, IP address, telephone number,‚Ä¶)</li>
                <li><strong>Processing</strong> = any operation which is performed on personal data (recording, storage, use, dissemination,‚Ä¶)</li>
              </ul>

              <p>‚úÖ <strong>4 General Rules for QA Professionals:</strong></p>

              <p><strong>Rule No. 1 üì¢:</strong><br>
              If you <strong>collect</strong> personal data, you must provide clear information to the individual (see art. 13).</p>

              <p><strong>Rule No. 2 ‚öôÔ∏è:</strong><br>
              If you <strong>process</strong> personal data, stick to the 7 GDPR principles (see art. 5):</p>
              <ol>
                <li><strong>Lawfulness, Fairness & Transparency:</strong> Be clear, honest, and lawful.</li>
                <li><strong>Purpose Limitation:</strong> Only use data for the reason you collected it.</li>
                <li><strong>Data Minimization:</strong> Collect only what you need.</li>
                <li><strong>Accuracy:</strong> Keep data correct and up to date.</li>
                <li><strong>Storage Limitation:</strong> Don‚Äôt keep data longer than necessary.</li>
                <li><strong>Integrity & Confidentiality:</strong> Keep data secure and protected.</li>
                <li><strong>Accountability:</strong> Be able to show you're compliant with GDPR.</li>
              </ol>

              <p><strong>Rule No. 3 üßæ:</strong><br>
              <strong>Lawful processing</strong> of personal data requires one of these six legal bases:</p>
              <ul>
                <li><strong>Consent:</strong> The individual has clearly agreed to the processing.</li>
                <li><strong>Contract:</strong> Necessary to perform or prepare a contract.</li>
                <li><strong>Legal Obligation:</strong> Required to meet a legal duty (pharmacovigilance etc).</li>
                <li><strong>Vital Interests:</strong> Needed to protect someone‚Äôs life.</li>
                <li><strong>Public Task:</strong> Carried out in the public interest or under official authority.</li>
                <li><strong>Legitimate Interests:</strong> For a valid business reason and only if not in conflict with individual privacy rights.</li>
              </ul>

              <p>‚ùó <strong>Important Note:</strong> If you‚Äôre dealing with data concerning health, there are higher standards (see art. 9).</p>

              <p><strong>Rule No. 4 üëÆ:</strong><br>
              If you process personal data as part of your <strong>core activities</strong> (clinical trial data for instance), get a DPO (Data Protection Officer) and conduct a Data Protection Impact Assessment.</p>

              <p>üö® <strong>What happens if I don‚Äôt play by the rules?</strong><br>
              You risk being publicly fined. Among the fined Belgian entities I found a hospital (‚Ç¨200k), a medical lab (‚Ç¨20k), the Belgian Order of Pharmacists (‚Ç¨30k),‚Ä¶</p>

              <p>üëâ Have a look yourself: <br> <a href="https://www.enforcementtracker.com/" target="_blank">https://www.enforcementtracker.com/</a></p>

            </div>
          </div>
        </div>
        <img class="case-media" src="GDPRinQA.jpg" alt="Image of a person standing on top of the 4 general rules of GDPR">





        <div class="case">
          <div class="case-title text-subtitle-p" ><strong>Death By CAPA: What is it? ‚Ä¶and how do you get out of it?</strong>
          </div>
          <div class="case-content">
            <div class="content-container text-body-p">
              
              <p>The CAPA system is the most beautiful system a QMS has to offer (granted, I might be a bit biased). 
              It enables organizations to plan, execute, verify effectiveness, and document actions that prevent the (re-)occurrence of systemic issues. 
              In other words: <em>it‚Äôs THE critical driver of continuous improvement.</em></p>

              <p>But‚Ä¶ there‚Äôs a risk.</p>

              <p><strong>Death By CAPA</strong> is the phenomenon where, for a prolonged period of time, CAPAs pile up faster than they‚Äôre being closed. 
              As the pile grows, usually so do the delays in closure‚Ä¶ resulting in:</p>

              <ul>
                <li><strong>Resource strain</strong></li>
                <li><strong>Bad metrics</strong> (which have a secondary effect during audits/inspections)</li>
                <li><strong>Prolonged exposure to risk</strong></li>
                <li>And (often overlooked but very real) <strong>impact on staff morale and engagement</strong></li>
              </ul>

              <p>Needless to say that these effects gradually ripple into the financial performance of your organization.</p>

              <p><strong><em>How do you know if your organization is at risk?</em></strong><br>
              It‚Äôs not always black or white, but telltale signs include overdue CAPAs, repeated deadline extensions, and a growing sense of ‚Äúnever catching up.‚Äù</p>

              <p>üëâ If this sounds familiar, you‚Äôre not alone. It‚Äôs exactly the type of challenges we help you tackle at <strong>CAPA Consulting</strong>.<br>
              From backlog removal to process redesign, <em>we bring you the results you need.</em><br>
              If your CAPA system is costing you more than it‚Äôs saving, <strong>let‚Äôs fix that.</strong></p>

              <p>üëá <em>Link in the comments below, or send a DM.</em></p>

            </div>
          </div>
        </div>
        <img class="case-media" src="DeathByCAPA.jpg" alt="Image of a person suffering under the weight of the CAPAs">






        <div class="case">

          <div class="case-title text-subtitle-p"><strong>And then Nutrivigilance came into effect‚Ä¶ Are you compliant?</strong>
          </div>

          <div class="case-content">
            <div class="content-container text-body-p">

              <p>Not strictly a QA topic today, but definitely a close cousin.<br>
              Nutrivigilance is often intertwined with the <strong>complaint handling process</strong>, yet still flies under the radar for many.</p>

              <p>üìå <strong><em>What is Nutrivigilance?</em></strong><br>
              It‚Äôs a vigilance system designed to <strong>rapidly identify undesirable effects</strong> linked to the consumption of certain foodstuffs.<br>
              Think <em>pharmacovigilance</em> for medicinal products or <em>materiovigilance</em> for medical devices, but applied to specific food products.</p>

              <p>In my experience, Nutrivigilance is too often:<br>
              ‚ùå Overlooked<br>
              ‚ùå Seen as ‚Äúless important‚Äù<br>
              ‚ùå Pushed down the priority list</p>

              <p>But here‚Äôs the reality:<br>
              ‚úÖ It became a <strong>legal obligation</strong> for many actors in the Belgian life sciences industry in <strong>December 2023.</strong></p>

              <p>In the slide deck below, you‚Äôll find:</p>
              <ul>
                <li>What Nutrivigilance is</li>
                <li>Why it matters</li>
                <li>Which products are in scope</li>
                <li>Who‚Äôs involved</li>
                <li>How proper reporting works</li>
              </ul>

              <p>üí° <strong>Last slide bonus:</strong> <em>7 practical tips for safe use of dietary supplements.</em></p>

              <p>If you‚Äôre involved and unsure whether your Nutrivigilance process is compliant, or if you need guidance building/supporting one:</p>

              <p>üì© Reach out here on LinkedIn or follow the link in the comments.</p>

            </div>
          </div>

        </div>
       <div class="carousel">
        <div class="carousel-track">
          <div class="carousel-slide"><img src="Dia1b.jpg" alt="Slide 1"></div>
          <div class="visually-hidden">
            <h3>Nutrivigilance: In a nutshell</h3>
            <p>
              RD 03 December 2023 ‚Äî An overview of nutrivigilance, its purpose, scope, and key stakeholders.
              Date: 11 August 2025.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia2b.jpg" alt="Slide 2"></div>
          <div class="visually-hidden">
            <h3>What &amp; Why?</h3>
            <p>
              Introduction to the concept of nutrivigilance, covering its purpose, legal basis, and the importance of monitoring undesirable effects related to nutrition-related products.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia3b.jpg" alt="Slide 3"></div>
          <div class="visually-hidden">
            <h3>Products in Scope</h3>
            <p>
              This includes:
              - Food supplements
              - Foodstuff for specific groups
              - Foods for special medical purposes
              - Novel foods
              - Fortified foods
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia4b.jpg" alt="Slide 4"></div>
          <div class="visually-hidden">
            <h3>Stakeholders</h3>
            <p>
              <strong>Operators:</strong> Any company involved in the product chain from manufacturing to availability to the consumer.
              Examples: Manufacturers, Distributors, Retailers.
              Legally obligated to report all undesirable effects within 10 working days.
            </p>
            <p>
              <strong>Healthcare Professionals:</strong> Doctors, Pharmacists, Dieticians, Nurses, Dentists, Speech Therapists, Physiotherapists, and others.
              Not legally obligated but expected to report undesirable effects when made aware.
            </p>
            <p>
              <strong>Citizens:</strong> Anyone who has knowledge of any undesirable effect, even if not personally experienced.
              Not legally obligated but can report undesirable effects when made aware.
            </p>
            <p>
              <strong>Organisations of Public Interest &amp; Public Utility Companies:</strong>
              Legally obligated to report all undesirable effects at least once per month.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia5b.jpg" alt="Slide 5"></div>
          <div class="visually-hidden">
            <h3>Reporting</h3>
            <p>
              Concomitant medication: Nutrivigilance works in collaboration with Pharmacovigilance.
            </p>
            <p>
              Scope: ‚ÄúAny suspected side effect that occurs on Belgian territory.‚Äù
            </p>
            <p>
              This includes:
              - Reporter
              - User
              - Product
              - Undesirable effect
              - Associated use
            </p>
            <p>
              Relevant attachments should be included with the report to provide complete context and documentation.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia6b.jpg" alt="Slide 6"></div>
          <div class="visually-hidden">
            <h3>Need Support?</h3>
            <p>
              This slide indicates where to seek help for reporting or understanding nutrivigilance processes.
              It includes all relevant contact details of CAPA Consulting.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia7b.jpg" alt="Slide 7"></div>
          <div class="visually-hidden">
            <h3>A Few Tips for Safer Consumption</h3>
            <p>
              Dietary supplements are not medicinal products and are not intended to prevent or treat disease.
              They should not replace medical treatment. If you are ill, consult your doctor.
            </p>
            <p>
              Be wary of miracle products and advertisements that try to convince you that a dietary supplement or other food product can cure or prevent illness.
            </p>
            <p>
              Ask your doctor or healthcare professional for advice before taking supplements.
            </p>
            <p>
              Follow the quantity, conditions of use, recommendations, and warnings given on the label.
            </p>
            <p>
              Take care when combining dietary supplements with medicinal products or other food supplements.
              If in doubt, consult your doctor or pharmacist.
            </p>
            <p>
              Avoid prolonged or repeated use of dietary supplements.
            </p>
            <p>
              Avoid buying dietary supplements or other food products from abroad via the internet.
            </p>
          </div>

        </div>
        <div class="carousel-controls">
          <button class="prevBtn">&#8592;</button> 
          <button class="nextBtn">&#8594;</button> 
        </div>
      </div>




        <div class="case">

          <div class="case-title text-subtitle-p">üö® <strong>Compliance Management: What it Really Means (and Why You Want to Avoid It at all cost)</strong>
          </div>

          <div class="case-content">
            <div class="content-container text-body-p">

              <p>
                I often compare a QMS system to a sailing ship. The goal of the QA team? Keep it afloat and on course (even when the weather gets bad or there‚Äôs a few holes in the hull).
              </p>

              <p>
                However, when the Competent Authorities start losing trust in your system, you are placed under <strong>Compliance Management</strong>.
                Once you‚Äôre under it‚Ä¶ getting out requires a lot (!) of additional effort.
              </p>

              <h3>üîç <strong>So... What is Compliance Management?</strong></h3>

              <p>
                It's a formal <em>escalation step</em> taken by the CA when inspectors determine that routine inspections are 
                <strong>no longer sufficient to ensure GMP/GDP compliance</strong>.

                In other words, your ship is now in a vortex.
              </p>

              <p>Once this process is triggered, you‚Äôre looking at:</p>
              <ul>
                <li><strong>Increased inspection frequency</strong> (to <em>every few months</em>)</li>
                <li><strong>Periodic monitoring and reporting</strong> (progress reports, compliance metrics,...)</li>
                <li><strong>Cautionary letters</strong> and <strong>Conditioned approvals</strong></li>
              </ul>

              <h3>‚ùó <strong>I‚Äôm in Compliance Management‚Ä¶ Now what?</strong></h3>

              <p>
                Either you <strong>successfully return to a state of compliance within the predefined period</strong>. <br><br>

                Or you <strong>fail to implement the required improvements within the predefined period</strong>, 
                leading to <strong>Regulatory Action</strong> (suspension of license for X months, license revoked, publication of a statement of non-compliance,‚Ä¶ the bad stuff).
              </p>

              <h3>üìà <strong>How do you get out of it?</strong></h3>

              <p>
                üëâ In short, you need to <strong>regain trust from the CA</strong>. We can help you with that by providing the required additional wind in your sails. 
                <strong>CAPA Consulting</strong> has first-hand experience in dealing with compliance management. 
                
              </p>

              <p><strong>As always, it's better to prevent than to cure.</strong></p>


            </div>
          </div>

        </div>
       <img class="case-media" src="compliance-whirlpool.png" alt="Image of a ship on the edge of a whirlpool">





        <div class="case">

          <div class="case-title text-subtitle-p">‚úÖ <strong>As promised, a deeper dive into the new EU GMP Annex 22 on Artificial Intelligence</strong>
          </div>

          <div class="case-content">
            <div class="content-container text-body-p">

              <p>
                A few weeks ago, I shared some initial thoughts on the upcoming <strong>Annex 22</strong> and its impact on the GMP environment.
              </p>

              <p>
                üìä I'm now pleased to share a <strong>dedicated slide deck</strong> that explores Annex 22 in more detail.
              </p>

              <p>
                üß† In addition, a <em>training session</em> will be organised in collaboration with <a href="https://www.upip-vapi.be/">UPIP-VAPI ‚Äì Belgian Professional Association of Pharmacists</a> working in the Life Science Industry in the coming months, covering:
              </p>
              <ul>
                <li>The new <strong>Annex 22</strong> (AI in GMP)</li>
                <li>The updated <strong>Annex 11</strong> (Computerised Systems)</li>
                <li>The revised <strong>Chapter 4</strong> (Documentation)</li>
              </ul>

              <p>üëâ Stay tuned if you‚Äôd like to be notified when registration opens.</p>

              <p>
                If you‚Äôre currently working with <strong>AI in a GMP context</strong>, or need support aligning your processes with <strong>Annex 22</strong> 
                (or any other GMP requirements), feel free to reach out. I‚Äôd be happy to assist.
              </p>

              <p>
                üìå <em>Note: The annex 22 is currently in draft (stakeholders consultation) until 7 October. 
                Nonetheless, it is highly unlikely that the content will undergo major changes from here.</em>
              </p>

              <p>Let‚Äôs keep the conversation going. üí¨</p>


            </div>
          </div>

        </div>
       <div class="carousel">
        <div class="carousel-track">
          <div class="carousel-slide"><img src="Dia1.jpg" alt="Slide 1"></div>
          <div class="visually-hidden">
            <h3>EU GMP New Annex 22 (draft): Artificial Intelligence Overview</h3>
            <p>This slide introduces Annex 22, focused on Artificial Intelligence within GMP. Date: 29 July 2025.</p>
          </div>
          <div class="carousel-slide"><img src="Dia2.jpg" alt="Slide 2"></div>
          <div class="visually-hidden">
            <h3>Scope</h3>
            <p>
              Key questions to determine if a computerized system is subject to Annex 22:
              1. Is it used in manufacturing of medicinal products or active substances?
              2. Does it directly impact patient safety, product quality, or data integrity?
              3. Is functionality obtained through data training (Machine Learning)?
              4. Does the model adapt over time with new data (Dynamic Model)?
              5. Does a specific input always yield a fixed output (Deterministic Model)?
            </p>
            <p>Note: If no direct impact, it may be used cautiously with a trained Human In The Loop (HITL), whose performance must be monitored.</p>
          </div>
          <div class="carousel-slide"><img src="Dia3.jpg" alt="Slide 3"></div>
          <div class="visually-hidden">
            <h3>Principle</h3>
            <p>
              The goal is understanding intended use and associated risks. Requirements include:
              - Close cooperation across all involved parties during algorithm selection, training, validation, testing, and operation.
              - Adequate qualifications and responsibilities.
              - Defined and appropriate access levels.
              - Availability and review of all documentation, even from third parties.
              - Quality Risk Management must assess risks to patient safety, product quality, and data integrity.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia4.jpg" alt="Slide 4"></div>
          <div class="visually-hidden">
            <h3>Intended Use</h3>
            <p>This slide defines the scope and purpose for which the AI model is implemented within GMP-regulated environments.</p>
          </div>
          <div class="carousel-slide"><img src="Dia5.jpg" alt="Slide 5"></div>
          <div class="visually-hidden">
            <h3>Acceptance Criteria</h3>
            <p>
              Test metrics (e.g., confusion matrix, accuracy, precision, F1-score) must be defined.
              Acceptance criteria must be clearly documented and assigned to the SME.
              If replacing an existing process, model performance must be at least as good as the original process.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia6.jpg" alt="Slide 6"></div>
          <div class="visually-hidden">
            <h3>Test Data</h3>
            <p>
              Test data must represent the full sample space, including all subgroups and variations.
              It should be large enough for statistically reliable metrics.
              Important considerations:
              - Pre-processing must be defined.
              - Any data exclusions must be documented.
              - AI-generated data is discouraged and must be justified if used.
              - Labels must be verified with high correctness.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia7.jpg" alt="Slide 7"></div>
          <div class="visually-hidden">
            <h3>Test Data Independence</h3>
            <p>
              Test data must be completely independent from training and validation data.
              Staff who accessed test data should not participate in training/validation.
              Access must be controlled, logged, and documented.
              No unauthorized copies of test data are allowed outside the designated repository.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia8.jpg" alt="Slide 8"></div>
          <div class="visually-hidden">
            <h3>Test Execution</h3>
            <p>
              The test must confirm model suitability for intended use and detect overfitting or underfitting.
              A formal test plan is required, including:
              - Intended use summary.
              - Pre-defined metrics and criteria.
              - Reference to test data.
              - Step-by-step test script.
              - Metric calculation methods.
              All deviations and failures must be documented and justified.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia9.jpg" alt="Slide 9"></div>
          <div class="visually-hidden">
            <h3>Explainability</h3>
            <p>
              During model testing, the features influencing decisions must be recorded (feature attribution).
              These features must be reviewed and justified (feature justification).
              Tools like SHAP values, LIME, or visual explanations may be used.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia10.jpg" alt="Slide 10"></div>
          <div class="visually-hidden">
            <h3>Confidence</h3>
            <p>
              This slide likely covers the importance of understanding and evaluating the confidence level of AI model outputs.
              Confidence metrics or scores should be available and interpreted appropriately to support reliable decision-making.
              Where confidence is low, human review or additional safeguards may be necessary.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia11.jpg" alt="Slide 11"></div>
          <div class="visually-hidden">
            <h3>Operations</h3>
            <p>
              Once a model has passed testing, it must be placed under configuration control before it is deployed in operational environments. This ensures protection against unauthorized changes.
            </p>
            <p>
              Ongoing monitoring of the model‚Äôs performance is essential. It should include:
              - System performance monitoring to detect degradation or anomalies.
              - Input sample space monitoring to check if incoming data remains within the range the model was trained for.
              - Detection of data drift, where input distributions shift over time.
            </p>
          </div>
          <div class="carousel-slide"><img src="Dia12.jpg" alt="Slide 12"></div>
          <div class="visually-hidden">
            <h3>Need Support?</h3>
            <p>
              This closing slide invites viewers to seek support if needed. It implies the availability of resources or contacts to assist with implementation or interpretation of Annex 22 requirements related to Artificial Intelligence.
            </p>
          </div>          
        </div>
        <div class="carousel-controls">
          <button class="prevBtn">&#8592;</button> 
          <button class="nextBtn">&#8594;</button> 
        </div>
      </div>



        <div class="case">
          <div class="case-title text-subtitle-p">‚ö†Ô∏è <strong>Avoid damage control. Mitigate your risks before they make headlines. üì∞</strong></h2>
          </div>
          <div class="case-content">
            <div class="content-container text-body-p">
            <p>
                <em>Deviations, Complaints, Out-Of-Specs, Reworks, Recalls, Breakdowns, Rejects,‚Ä¶</em><br>
                They all come with a <strong>hefty price tag üí∏</strong> if you <em>really think about it</em>.
              </p>

              <p>
                At <strong>CAPA Consulting</strong>, we create new and optimize existing <strong>QMS systems</strong> based on 
                <em>independent risk assessments</em>.<br>
                <strong>The goal?</strong> To keep your operational cost of QA activities as low as possible without compromising compliance. ‚úÖ
              </p>

              <p>
                üì© <em>Want to hear more?</em><br>
              </p>
            </div>
          </div>
        </div>
        <img class="case-media" src="meme-Astronomer-QRM.jpg" alt="Meme of viral Astronomer CEO kiss-cam">





        <div class="case" style="border-bottom-left-radius: 8px; border-bottom-right-radius: 8px">
          <div class="case-title text-subtitle-p" >üí°<strong>Significant changes ahead in the realm of GDP</strong>
          </div>
          <div class="case-content">
            <div class="content-container text-body-p">
              
            <p>
              Yesterday, I attended the EIPG webinar on the revision of the <strong>Good Distribution Practice (GDP)</strong> guidelines. Some interesting insights were shared:
            </p>

            <p>üîç <strong>Key Takeaways:</strong></p>
            <ul>
              <li>GDP will no longer be a <em>guideline</em> ‚Äî it‚Äôs becoming an <strong>EU Regulation</strong>.</li>
              <li>üìå <strong>Harmonisation</strong> across EU member states is the main objective.</li>
              <li>The <strong>EMA</strong> is responsible for drafting the text, <strong>based on input from the Inspectors Working Group.</strong></li>
            </ul>

            <p>üë§ <strong>What does this mean for Responsible Persons (RPs)?</strong></p>
            <ul>
              <li>For the first time, the role and responsibilities of the RP will be defined directly in <strong>EU legislation</strong>.</li>
            </ul>

            <p>üìú <strong>New focus areas include:</strong></p>
            <ul>
              <li>The use of <strong>AI</strong></li>
              <li><strong>Cybersecurity</strong> measures (!)</li>
              <li>Reducing audit fatigue through <strong>Joint Audits</strong></li>
            </ul>

            <p>üìÖ <strong>Expected Implementation Timeline:</strong> 2027 ‚Äì 2028</p>

            <p>üëè Special thanks to <a href="https://www.eipg.eu/">European Industrial Pharmacists Group</a> for organizing this webinar which offered an exclusive look behind the scenes.</p>

            </div>
          </div>
        </div>




        <div class="case" style="border-bottom-left-radius: 8px; border-bottom-right-radius: 8px">
          <div class="case-title text-subtitle-p">üö® <strong>Major EU GMP Updates in the pipeline: Drafts for Annex 11, Chapter 4 & NEW Annex 22 (AI) Now Open for Consultation</strong>
          </div>
          <div class="case-content">
            <div class="content-container text-body-p">

            <p><strong>Key Details:</strong></p>
            <ul>
              <li>üìÖ <strong>Consultation Window:</strong> July 7 ‚Äì October 7, 2025</li>
              <li>üîç <strong>Scope:</strong>
                <ul>
                  <li>Revised <strong>Annex 11</strong> (Computerised Systems)</li>
                  <li>Updated <strong>Chapter 4</strong> (Documentation)</li>
                  <li>Brand-new <strong>Annex 22</strong> (AI in Pharma Manufacturing)</li>
                </ul>
              </li>
              <li>üèõÔ∏è <strong>Developed by:</strong> EMA & PIC/S to harmonize digital/GMP standards globally.</li>
            </ul>

            <h3><strong>Highlights of Proposed Changes</strong></h3>

            <h4>üî¨ <strong>NEW Annex 22: AI in GMP</strong></h4>
            <ul>
              <li><strong>Scope:</strong> Only <em>static, deterministic AI models</em> permitted for critical applications (e.g., product release).</li>
              <li><strong>Exclusions:</strong> Generative AI/LLMs banned from critical processes; "human-in-the-loop" required for non-critical uses.</li>
              <li><strong>Critical Rules:</strong> Model explainability (e.g., SHAP/LIME), confidence scoring, and lifecycle monitoring.</li>
            </ul>

            <h4>üîí <strong>Revised Annex 11: Computerised Systems</strong></h4>
            <ul>
              <li><strong>Security:</strong> Mandates MFA, penetration testing, and network segmentation.</li>
              <li><strong>Data Integrity:</strong> Audit trails now <em>required</em> (not risk-based).</li>
              <li><strong>Quality Integration:</strong> Direct links to Pharmaceutical Quality Systems (PQS) for deviations/CAPA.</li>
            </ul>

            <h4>üìÑ <strong>Revised Chapter 4: Documentation</strong></h4>
            <ul>
              <li><strong>ALCOA++ Principles:</strong> "Traceable + Enduring" standards for <em>all</em> data (text, images, audio).</li>
              <li><strong>Hybrid Systems:</strong> Clear governance for electronic signatures and cloud-based solutions.</li>
              <li><strong>Lifecycle Control:</strong> Risk-based retention/disposal protocols.</li>
            </ul>

            <h3><strong>Why This Matters</strong></h3>
            <p>
              These updates modernize EU GMP for the digital age ‚Äî integrating AI governance, cybersecurity rigor, and end-to-end data integrity. Annex 22 sets a pioneering standard for trustworthy AI in pharma.
            </p>

            <p>üîú <strong>Coming Soon:</strong> I‚Äôll break down the implications of each proposed change in more detail. <em>Stay tuned!</em></p>

            </div>
          </div>
        </div>






        <div class="case" style="border-bottom-left-radius: 8px; border-bottom-right-radius: 8px">
          <div class="case-title text-subtitle-p">üöÄ <strong>Proactive vs. Reactive Quality: Stop Fighting Fires ‚Äî Start Preventing Them</strong>
          </div>
          <div class="case-content">
            <div class="content-container text-body-p">
              

            <p><em>(Less ‚ÄúOops‚Äù ‚Äî more ‚ÄúAaaah!‚Äù)</em></p>

            <p>
              Waiting for problems to hit wastes time, money, and can jeopardize patient safety. Instead, shift to a <strong>proactive quality mindset</strong> ‚Äî where issues are prevented before they happen. 
              It‚Äôs a game-changer for <strong>compliance</strong> and <strong>efficiency of your QMS.</strong>
            </p>

            <h3>üîç <strong>Key Contrasts:</strong></h3>
            <ul>
              <li><strong>Reactive:</strong> Occurrence ‚Üí Detection ‚Üí Correction <br />(High cost, Always late, Firefighting mode)</li>
              <li><strong>Proactive:</strong> Assess ‚Üí Prevent ‚Üí Review <br />(Low cost, Forward-thinking, Quality-driven culture)</li>
            </ul>

            <h3>‚úÖ <strong>Why Proactive Wins:</strong></h3>
            <ul>
              <li><strong>Cost Savings</strong> ‚Äì Prevention slashes correction costs and waste</li>
              <li><strong>Safety & Compliance</strong> ‚Äì Fewer deviations and failures</li>
              <li><strong>Regulatory Alignment</strong> ‚Äì Most modern GxP guidelines support and encourage risk-based strategies</li>
            </ul>

            <h3>üëâ <strong>Shift Your Mindset:</strong></h3>
            <p>
              Go from ‚Äú<em>Are we compliant enough?</em>‚Äù to ‚Äú<em>How do we prevent failure tomorrow?</em>‚Äù
            </p>

            <p>
              üí¨ Interested in going proactive? <br />
            </p>

            <p>
              Need tailored support? <strong>CAPA Consulting</strong> can help optimize your Quality System.<br />
            </p>



            </div>
          </div>
        </div>



        <div class="case">
          <div class="case-title text-subtitle-p"><strong>Two weeks after launching CAPA Consulting, I found myself in China - Leading an EU GMP audit at a sterile manufacturing site with over 1,200 employees.</strong> üåç‚úàÔ∏è
          </div>
          <div class="case-content">
            <div class="content-container text-body-p">
              
              <p>
                It was an incredible experience:<br />
                An international project, a top-tier facility, and the opportunity to work alongside two brilliant co-auditors (and now, new friends).
              </p>

              <p>
                Audits aren‚Äôt just about compliance ‚Äî they‚Äôre moments of <strong>cross-pollination</strong>.<br />
                I learned a lot.<br />
                I shared a lot.<br />
                And most rewarding of all: I witnessed teams thinking <em>together</em> to solve findings not by adding more procedures, but by <strong>improving the design</strong> of the existing system.
              </p>

              <p><strong>That's real quality culture in action.</strong> üôå</p>

              <p>
                Beyond the audit, I gained a deeper appreciation for the local culture ‚Äî The hospitality, work ethic, and the commitment to continuous improvement truly stood out.
              </p>

              <p>
                If you‚Äôre looking for support with <strong>EU GMP</strong> or <strong>GDP audits</strong> ‚Äî whether in Europe or abroad ‚Äî don‚Äôt hesitate to reach out. I‚Äôd be happy to support you.
              </p>

            </div>
          </div>
        </div>
        <img class="case-media" src="audit-china.jpg" alt="Selfie of me in Shanghai airport">



        <div class="case">
          <div class="case-title text-subtitle-p"><strong>Yesterday, I attended the GDP/RP refresher training organised by <a href="https://www.upip-vapi.be/">UPIP-VAPI</a> at <a href="https://www.clinigengroup.com/">Clinigen</a></strong> 
          </div>
          <div class="case-content">
            <div class="content-container text-body-p">
            <p>it was a great reminder of how essential training is in maintaining a strong quality culture.</p>

           <p>As outlined in the GDP guidelines:<br>
              <em>"Personnel should receive initial and continuing training relevant to their role‚Ä¶. The responsible person should also maintain their competence in GDP through regular training."</em>
            </p>

            <p>It's a simple statement ‚Äî but there‚Äôs a lot behind it.</p>

            <p>üìö <strong><em>Training is not just a requirement ‚Äî it's a backbone of quality.</em></strong><br>
              That perfect SOP is useless if stakeholders don‚Äôt know what‚Äôs in it, or worse, don‚Äôt follow it. That‚Äôs why training should never be treated as a checkbox exercise.
            </p>

            <p><strong><em>What resonated most?</em></strong> The real-world case studies. Let‚Äôs be honest: reality loves throwing curveballs ‚öæÔ∏è, and applying GDP principles often stretches beyond the written guidelines.</p>

            <p>üëè Special thanks to Frank Peeters, Ludwig Everaert and Rizovsky Mounir for organising such a valuable event!</p>

            <p>üîç <strong><em>Do you struggle with training in your organisation?</em></strong><br>
              Whether it's engagement, consistency, or real-world application ‚Äî let‚Äôs talk. I‚Äôd love to hear where your challenges lie and explore how we can help.
            </p>

            <p><strong><em>P.S. Are you active as RP?</em></strong> Don‚Äôt forget to attend a GDP refresher training frequently ‚Äî it‚Äôs a detail that inspectors always check during GDP inspections.</p>

            </div>
          </div>
        </div>
        <img class="case-media" src="RP-training.jpg" alt="Image of classroom during training">
      </div>

	</div>
  <div class="main-container-inner-3">
    <div class="sub-container-inner-4">
      <h2 class="text-top-title-p selector2">Got a question?</h2>
      <p class="text-body-p selector3">Get in touch via the link below.
      </p>
      <div class="button-layout-div">
        <a href="/contact" class="button-layout">Contact us</a>
      </div>
    </div>
  </div>

</main>

<footer class="footer-container-outer" role="contentinfo">
	<div class="footer-container-inner">
		<div class="sub-container-footer-top">

			<div class="sub-sub-container-footer-top">
				<div class="footer-text-left-row-1">
					<p class="bold">CAPA Consulting</p>
					<p class="bold">BE1022.648.333</p>
				</div>
				<div class="footer-text-left-row-2">
					<p class="footer-text-left-row-2">nicolas@CAPAconsulting.be</p>
					<img src="telefoonnummer.PNG" class="antibototics" alt="Telephone number">
				</div>
			</div>
			<div class="footer-text-middle">
				<a href="/terms-of-use" class="footer-text-right">Terms of use</a>
			</div>
			<div class="footer-text-middle">
				<p class="footer-text-middle"></p>
			</div>
			<div class="footer-text-middle">
				<a href="/privacy-policy" class="footer-text-right">Privacy Policy</a>
			</div>
			<div class="sub-sub-container-footer-top">
				<a class="footer-text-right bold" id="backToTop" style="cursor: pointer;">Back to top</a>
				<p class="footer-text-right">CAPA Consulting copyrights</p>
			</div>
		</div>
		<div class="sub-container-footer-bottom">
			<a href="/index" class="footer-logo"><img src="logo-footer.png" class="footer-logo"></a>
		</div>
	</div>
</footer>

<script>
  document.getElementById('backToTop').addEventListener('click', function () {
    gsap.to(window, { duration: 1, scrollTo: 0, ease: "power3.inOut" });
  });
</script>

<script>
  document.addEventListener("DOMContentLoaded", () => {
    const elements = document.querySelectorAll('.fade-in-up');
    elements.forEach((el, index) => {
      el.style.animationDelay = `${index * 100}ms`;
    });
  });
</script>

<script>
    gsap.registerPlugin(ScrollTrigger);
    ScrollTrigger.matchMedia({
      "(min-width: 769px)": function() {

        gsap.from(".symbol-top", {
          scrollTrigger: {
            trigger: ".symbol-top",
            start: "top 70%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
        });

        gsap.from(".text-top-title-div", {
          scrollTrigger: {
            trigger: ".text-top-title-div",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
          delay: 0.2,
        });

        gsap.from(".main-container-inner-2", {
          scrollTrigger: {
            trigger: ".main-container-inner-2",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
          delay: 0.4,
        });

        gsap.from(".case", {
          scrollTrigger: {
            trigger: ".main-container-inner-2",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
        });


        gsap.from(".selector2", {
          scrollTrigger: {
            trigger: ".selector2",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
        });

       gsap.from(".selector3", {
          scrollTrigger: {
            trigger: ".selector3",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
        });
       gsap.from(".button-layout-div", {
          scrollTrigger: {
            trigger: ".selector3",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
          delay:0.3,
        });


      },

      "(max-width: 769px)": function() {

        gsap.from(".symbol-top", {
          scrollTrigger: {
            trigger: ".symbol-top",
            start: "top 70%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
        });

        gsap.from(".text-top-title-div", {
          scrollTrigger: {
            trigger: ".text-top-title-div",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
          delay: 0.2,
        });

        gsap.from(".main-container-inner-2", {
          scrollTrigger: {
            trigger: ".main-container-inner-2",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
          delay: 0.4,
        });

        gsap.from(".case", {
          scrollTrigger: {
            trigger: ".case",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
        });


        gsap.from(".selector2", {
          scrollTrigger: {
            trigger: ".selector2",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
        });

       gsap.from(".selector3", {
          scrollTrigger: {
            trigger: ".selector3",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
        });
       gsap.from(".button-layout-div", {
          scrollTrigger: {
            trigger: ".selector3",
            start: "top 80%",
            toggleActions: "play none none none",
          },
          opacity: 0,
          y: 30,
          scale: 1,
          duration: 0.7,
          delay:0.3,
        });


      },
   });
</script>
<script>
  document.querySelectorAll('.case-title, .case-media').forEach(title => {
    title.addEventListener('click', () => {
      let caseElement;

      // Determine the associated .case element
      if (title.classList.contains('case-media')) {
        // The image is *after* the .case, so go to the previous sibling
        caseElement = title.previousElementSibling;
      } else {
        // The title is *inside* the .case
        caseElement = title.closest('.case');
      }

      const content = caseElement.querySelector('.case-content');
      const isOpen = caseElement.classList.contains('open');

      if (isOpen) {
        content.style.maxHeight = '0';
        content.style.paddingTop = '0';
        content.style.paddingBottom = '0';
        caseElement.classList.remove('open');
      } else {
        content.style.maxHeight = content.scrollHeight + 'px';
        content.style.paddingTop = '15px';
        content.style.paddingBottom = '15px';
        caseElement.classList.add('open');
      }
    });
  });
</script>

<script>
document.querySelectorAll('.carousel').forEach(carousel => {
  const track = carousel.querySelector('.carousel-track');
  const slides = carousel.querySelectorAll('.carousel-slide');
  const nextBtn = carousel.querySelector('.nextBtn');
  const prevBtn = carousel.querySelector('.prevBtn');
  
  let currentIndex = 0;

  function setSlideWidths() {
    const carouselWidth = carousel.clientWidth;
    slides.forEach(slide => {
      slide.style.width = `${carouselWidth}px`;
    });
    goToSlide(currentIndex);
  }

  function goToSlide(index) {
    const slideWidth = slides[0].clientWidth;
    const x = -index * slideWidth;
    gsap.to(track, { x, duration: 0.6, ease: "power2.inOut" });
  }

  nextBtn.addEventListener('click', () => {
    if (currentIndex < slides.length - 1) {
      currentIndex++;
      goToSlide(currentIndex);
    }
  });

  prevBtn.addEventListener('click', () => {
    if (currentIndex > 0) {
      currentIndex--;
      goToSlide(currentIndex);
    }
  });

  window.addEventListener('resize', setSlideWidths);
  setSlideWidths();
});
</script>



</body>

</html>